# In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

> **NCT01430390** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** Biological/Genetically Modified T cells
- **DRUG:** Cyclophosphamide-based chemotherapy

## Key facts

- **NCT ID:** NCT01430390
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-09
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430390, "In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01430390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*